Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Brief introduction:
It is a medical device company based in Skona, Sweden, which is a leader in the development of non-pharmacological treatments for allergic severe asthma and eczema.
Company Advantages:
The company offers non-invasive devices for home therapy based on proprietary temperature controlled laminar flow technology (TLA).
Users can use the company's products for treatment during rest and sleep, and use of the device can significantly reduce allergens and other airborne irritants in the patient's breathing area.
The device is a Class 1 CE-certified medical device designed to relieve symptoms of allergic diseases such as allergic asthma and eczema.
The product complies with EU requirements on design, function and safety and has undergone rigorous clinical studies as well as health economic studies.
The product is now FDA-approved for Class 510 (k) II approval.
Cooperation intention
Currently, the company is looking for Chinese partners to jointly expand the Chinese market.